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Frontiers in Oncology | www.frontiersin.orgBackground: Three or four cycles of cisplatin-based chemotherapy is the standard
neoadjuvant treatment prior to cystectomy in patients with muscle-invasive bladder cancer.
Although NCCN guidelines recommend 4 cycles of cisplatin-gemcitabine, three cycles are also
commonly administered in clinical practice. In this multicenter retrospective study, we assessed
a large and homogenous cohort of patients with urothelial bladder cancer (UBC) treated with
three or four cycles of neoadjuvant cisplatin-gemcitabine followed by radical cystectomy, in
order to explore whether three vs. four cycles were associated with different outcomes.
Methods: Patients with histologically confirmed muscle-invasive UBC included in this
retrospective study had to be treated with either 3 (cohort A) or 4 (cohort B) cycles of
cisplatin-gemcitabine as neoadjuvant therapy before undergoing radical cystectomy with
lymphadenectomy. Outcomes including pathologic downstaging to non-muscle invasive
disease, pathologic complete response (defined as absence of disease -ypT0), overall-
and cancer-specific- survival as well as time to recurrence were compared between
cohorts A vs. B.
Results: A total of 219 patients treated at 14 different high-volume Institutions were
included in this retrospective study. Patients who received 3 (cohort A) vs. 4 (cohort B)
cycles of neoadjuvant cisplatin-gemcitabine were 160 (73,1%) vs. 59 (26,9%).At univariate
analysis, the number of neoadjuvant cycles was not associated with either pathologic
complete response, pathologic downstaging, time to recurrence, cancer specific, and
overall survival. Of note, patients in cohort B vs. A showed a worse non-cancer specific
overall survival at univariate analysis (HR= 2.53; 95 CI= 1.05 - 6.10; p=0.046), although
this finding was not confirmed at multivariate analysis.
Conclusions: Our findings suggest that 3 cycles of cisplatin-gemcitabine may be equally
effective, with less long-term toxicity, compared to 4 cycles in the neoadjuvant setting.Keywords: bladder cancer, neoadjuvant chemotherapy, radical cystectomy, observational study, cisplatin-
based chemotherapyINTRODUCTION
Bladder cancer represents approximately 3% of cancer diagnoses
in the world, with a 4-time higher prevalence in males vs. females
and >90% of cases diagnosed in individuals older than 55 years of
age (1). Age-standardized incidence rates of approximately 20
cases per 100,000 per year in males and 4.5 cases per 100,000 per
year in females are reported in Europe and North America (2),
with certain areas of Italy showing remarkably higher rates [e.g.
in the province of Naples, Italy, an age-standardized incidence
rate of 75.3 and 16.3 cases per 100,0000 per year in males and
females, respectively, has been reported (3)].
While chemotherapy agents such as mitomycin and
gemcitabine (4) can be used for intravesical therapy against
non-invasive bladder cancer, intravesical BCG represents the
standard therapy for patients with T1 disease (5), and cystectomy
(6–8), with or without perioperative chemotherapy (9), is
recommended for muscle-invasive, localized bladder cancer
(10). Advances in the field of peri-operative systemic therapy
of muscle-invasive bladder cancer have been scarce over the past
20 years. Neoadjuvant chemotherapy regimens based on
methotrexate, vinblastine, doxorubicin cisplatin or cisplatin-2
gemcitabine were associated with an absolute increase in 5-
year survival of 8% in patients with muscle invasive-bladder
cancer (9). Although neoadjuvant cisplatin-based chemotherapy
is currently recommended by NCCN (10) and EAU (11)
guidelines in patients with muscle-invasive UBC, the optimal
chemotherapy schedule and number of cycles remain to be
established. According to NCCN guidelines, dose-dense
methotrexate, vinblastine, doxorubicin, cisplatin combination
can be administered for 3 or 4 cycles, while cisplatin,
methotrexate and vinblastine combination is administered for
3 cycles. Four cycles of gemcitabine and cisplatin represent a
viable option in the perioperative setting, on the grounds of the
results obtained in a large randomized phase III trial (12)and of
retrospective case series (13). Nevertheless, the optimal number
of cycles of cisplatin-gemcitabine remains therefore to be
determined, given the lack of comparative studies specifically
designed to assess optimal number of cycles.
In this multicenter retrospective study, we assessed a large
and homogenous cohort of patients with histologically
confirmed urothelial bladder cancer (UBC) treated with 3 vs. 4
neoadjuvant cisplatin-based chemotherapy followed by radical
cystectomy, to explore potential differences in outcomes in termsMay 2021 | Volume 11 | Article 651745
Ferro et al. Neoadjuvant Chemotherapy for Bladder Cancerof cancer specific-, non-cancer specific, overall- survival, time to
recurrence and pathologic response and downstaging rates.PATIENTS AND METHODS
Patients
All patients with UBC treated with neoadjuvant chemotherapy at
the participating Institutions from January 2000 until January
2015 had to be assessed for inclusion in this retrospective study.
Patients were included in this retrospective study if they had
histologically confirmed muscle-invasive bladder cancer with
predominant urothelial component and were treated with 3 or 4
cycles of cisplatin-gemcitabine (gemcitabine 1000-1250 mg/m2 on
days 1 and 8, and cisplatin 70 mg/m2 on day 1, every 3 weeks) as
neoadjuvant therapy before undergoing radical cystectomy with
lymphadenectomy. Only patients with cT1-4N0M0 on whole
body CT scan with and without contrast prior to chemotherapy
start and with a follow-up after surgery longer than 36 months
were included in this retrospective study. Follow-up was
conducted with a whole CT scan with and without contrast
every 3-6 months and additional tests (MRI, bone scan) if
clinically indicated. Data about sex, age, ECOG performance
status, Charlson Comorbidity index, previous number of cycles
of cisplatin-based neoadjuvant therapy, hemoglobin, creatinine,
absolute neutrophil and lymphocyte counts, total and HDLFrontiers in Oncology | www.frontiersin.org 3cholesterol, CRP, presence of histologically proven positive
lymph-nodes, and cancer-specific survival (months) were
required to have been measured within 14 days and be fully
available for the patient to be included in this retrospective study.
Date and cause of death were collected using death certificates and
ISTAT (Italian National Institute of Statistics) cause of death
records. These variables were considered as potentially
prognostic and assessed for their association with cancer specific
survival. Information regarding recurrence was extracted from
medical charts. Retrospective observation started on the day of
cystectomy until death or last follow-up.
Statistical Analysis
Descriptive statistics were used to describe the overall cohort
with respect to the main demographical and clinical
characteristics. Frequencies (percentages) were used for
categorical variables, while medians (Q1; Q3), were used for
quantitative variables. Associations between the number of cycles
along with other potential predictive factors and the outcome
variables downstaging and complete response were evaluated
using univariate logistic regression models. Additionally,
variables that presented a significant association in the
univariate analysis were added to a multivariate logistic
regression model. Time-to-event outcome variables were
analyzed estimating survival curves with the Kaplan-Meier
method and the difference between the curves was computed
using log-rank test (Figures 1–4). The association of the numberFIGURE 1 | Kaplan-Meier curves with 95% CI (dashed lines). P-value computed with log-rank test (overall survival).May 2021 | Volume 11 | Article 651745
Ferro et al. Neoadjuvant Chemotherapy for Bladder CancerFIGURE 2 | Kaplan-Meier curves with 95% CI (dashed lines). P-value computed with log-rank test (cancer specific survival).FIGURE 3 | Kaplan-Meier curves with 95% CI (dashed lines). P-value computed with log-rank test (non-cancer survival).Frontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 6517454
Ferro et al. Neoadjuvant Chemotherapy for Bladder Cancerof cycles and other variables of potential interest with overall
survival, cancer-specific survival and recurrence was conducted
using univariate Cox regression. Factors that presented a
p-value < 0.1 were added, along with the variable of interest
(number of cycles), to a multivariate Cox regression model. The
proportional hazard assumption was tested using the Schoenfeld
residuals. For all analyses, a p-value < 0.05 was considered
statistically significant. Analyses were performed using the
statistical software R, version 4.0.3.RESULTS
Patients’ Baseline Characteristics
A total of 245 patients receiving neoadjuvant cisplatin-
gemcitabine at 14 different high-volume Institutions were
initially evaluated for inclusion in this retrospective study.
After excluding 7 patients who received 6 cycles, 3 patients
who received 1 cycle, 13 patients who received 2 cycles and 3
patients with missing data, a total of 219 patients receiving 3 or 4
cycles were included in this retrospective study. Patients who
received 3 (cohort A) vs. 4 (cohort B) cycles of neoadjuvant
cisplatin-gemcitabine were 160 (73,1%) vs. 59 (26,9%). In cohort
A, 83.1% were males and median age was 66 (IQR = 59,000
to 72,00).Frontiers in Oncology | www.frontiersin.org 5In cohort B, median age was 66 years (IQR = 59,000 to 72,00),
and 81.4% were males. Patients’ characteristics are detailed in
Table 1.
Outcomes
After a median follow-up of 76 months, median overall survival
was not reached in cohort A, with 43 reported deaths (34 because
of bladder cancer), while it was 110 months (95%CI: 81-120) in
cohort B, with 24 reported deaths (15 because of bladder cancer).
Median cancer-specific survival and time to recurrence were not
reached in either cohort. Pathologic downstaging to non-muscle
invasive disease was reported in 129 and 43 patients in cohort A
and B, respectively. Complete pathologic response was reported
in 36 (22.5%) and 13 (22.0%) patients in cohort A and B,
respectively, while recurrence was reported in 46 (28.7%) vs.
17 (28.8%) patients in cohorts A vs. B, respectively.
Three-year estimated OS probability was 89.8% (82.4-97.9)
for cohort A compared to 94.4% (90.9-98.0) for cohort B. Three-
year estimated cancer-specific survival probability was 96.3%
(93.4-99.2) for cohort A compared to 93.2% (87.9-99.9) for
cohort B. Three-year estimated OS probability was 92.4%
(88.4-96.4) for those who did not have a complete response
compared to 95.9% (90.5-100.0) for those who had a complete
response. Three-year estimated recurrence-free survival
probability was 71.3% (64.6-78.6) for cohort A compared to
71.2% (60.5-83.7) for cohort B. Three-year estimated non-cancerFIGURE 4 | Kaplan-Meier curves with 95% CI (dashed lines). P-value computed with log-rank test (recurrence).May 2021 | Volume 11 | Article 651745
Ferro et al. Neoadjuvant Chemotherapy for Bladder Cancersurvival probability was 97.6% (95.0-100.0) for cohort A
compared to 95.5% (89.5-100.0) for cohort B. Three-year
estimated cancer-specific survival probability was 94.7% (91.4-
98.1) for those who did not have a complete response compared
to 98.0% (94.1-100.0) for those who had a complete response.
Three-year estimated OS probability was 87.2% (78.2-97.3) for
those who did not have downstaging compared to 94.8% (91.5-
98.2) for those who had downstaging. Three-year estimatedFrontiers in Oncology | www.frontiersin.org 6cancer-specific survival probability was 89.4% (81.0-98.6) for
those who did not have downstaging compared to 97.1% (94.6-
99.6) for those who had downstaging. Three-year estimated
recurrence-free survival probability was 68.1% (56.0-82.8) for
those who did not have downstaging compared to 72.1% (65.7-
79.1) for those who had downstaging.
Five-year estimated OS probability was 76.9% (70.4-83.9) for
cohort A compared to 72.3% (61.3-85.4) for cohort B. Five-yearTABLE 1 | Characteristics of the study population.
Number of cycles of cisplatin-gemcitabine p-value
3 (COHORT A) 4 (COHORT B)
Median (IQR range) Mean (SD) Median (IQR range) Mean (SD)
Age 66 (59, 72) 66 (10) 66 (60, 74) 67 (10) 0.762
Basophils x103/µL 0.03 (0.02, 0.05) 0.05 (0.06) 0.03 (0.01, 0.05) 0.04 (0.05) 0.283
Charlson index 3.00 (2.00, 5.00) 3.79 (2.11) 2.00 (2.00, 3.00) 2.73 (1.48) <0.001
Eosinophils x103/µL 0.12 (0.08, 0.22) 0.20 (0.27) 0.13 (0.07, 0.21) 0.28 (0.83) 0.817
Lymphocytes x103/µL 1.88 (1.50, 2.41) 2.42 (2.91) 1.81 (1.43, 2.41) 2.17 (2.14) 0.344
Monocytes x103/µL 0.70 (0.45, 1.19) 1.25 (1.48) 0.72 (0.54, 1.04) 1.14 (1.17) 0.427
Neutrophils x103/µL 4.39 (3.20, 5.74) 6.10 (9.05) 4.44 (3.42, 5.89) 5.87 (9.06) 0.725
NLR 2.21 (1.59, 3.25) 2.71 (1.66) 2.30 (1.70, 3.75) 2.87 (1.67) 0.553
PCR (mg/L) 8 (4, 13) 10 (10) 8 (5, 13) 10 (8) 0.929
Platelets x103/µL 232 (190, 320) 261 (104) 253 (187, 334) 260 (87) 0.750
Preoperative PCR (mg/L) 7 (3, 12) 9 (7) 5 (2, 8) 6 (6) 0.033
Albumin (g/dl) 3.90 (3.50, 4.21) 3.84 (0.53) 3.80 (3.40, 4.05) 3.69 (0.49) 0.065
BMI 26.0 (23.0, 28.0) 25.9 (3.6) 25.1 (23.2, 28.6) 25.9 (3.7) 0.903
Creatinine (mg/dl) 1.05 (0.87, 1.38) 1.22 (0.70) 0.97 (0.85, 1.23) 1.08 (0.37) 0.145
Fibrinogen level (mg/dl) 2.58 (2.09, 4.25) 3.24 (1.27) 2.23 (2.04, 3.59) 2.89 (1.07) 0.119
HB (g/dl) 12.85 (11.0, 14.4) 15.34 (17.43) 12.5 (11.25, 14.4) 12.72 (1.94) 0.938
HDL cholesterol (mg/dl) 45 (36, 57) 48 (14) 55 (44, 64) 52 (14) 0.035
Total cholesterol level (mg/dl) 198 (175, 210) 201 (37) 203 (184, 230) 206 (40) 0.225
SED rate (mm/h) 19 (8, 30) 21 (16) 15 (6, 23) 17 (13) 0.204
Absolute Number % Absolute Number %
Gender
Males 133 83.1% 48 81.4% 0.916
Females 27 16.9% 11 18.6%
ECOG Performance status
0 79 49.4% 44 74.6% 0.007
1 62 38.7% 9 15.2%
2 10 6.3% 3 5.1%
3 4 2.5% 1 1.7%
4 5 3.1% 2 3.4%
Clinical T stage 0.65
<=2 95 59.7% 37 62.7%
>=3 65 40.3% 22 37.3
Clinical N stage
0 160 100% 59 100%
Pathologic stage
Ta 6 3.7% 3 5.1% 0.110
T1 11 6.9% 7 11.9%
T2 40 25.0% 6 10.2%
T3 43 26.9% 16 27.1%
T4 14 8.7% 11 18.6%
T0 36 22.5% 13 22.0%
Tis 10 6.3% 3 5.1%
N0 110 68.8% 39 66.1% 0.073
N1 19 11.9% 4 6.8%
N2 18 11.2% 11 18.6%
N3 5 3.1% 5 8.5%
Nx 8 5.0% 0 0.0%May 2021 | Volume 11 | ArticleP-values computed with Student’s t test or Kruskal Wallis test as appropriate for continuous variables, and with Chi-square test or Fisher’s exact test as appropriate for categorical
variables. Significant values are highlighted in bold. BMI, Body Mass Index; SED rate, Sedimentation rate.651745
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88.2) for cohort A compared to 81.1% (71.2-92.5) for cohort B.
Five-year estimated recurrence-free survival probability was
71.3% (64.6-78.6) for cohort A compared to 71.2% (60.5-83.7)
for cohort B. Five-year estimated non-cancer survival probability
was 92.4% (87.7-97.3) for cohort A compared to 87.1% (77.1-
98.4) for cohort B. Five-year estimated OS probability was 72.1%
(65.5-79.5) for those who did not have a complete response
compared to 88.4% (79.2-98.6) for those who had a complete
response. Five-year estimated cancer-specific survival probability
was 77.7% (71.5-84.6) for those who did not have a complete
response compared to 95.2% (88.9-100.0) for those who had a
complete response. Five-year estimated recurrence-free survival
probability was 71.8% (65.3-78.9) for those who did not have a
complete response compared to 69.4% (57.6-83.6) for those who
had a complete response. Five-year estimated OS probability was
69.7% (57.6-84.3) for those who did not have downstaging
compared to 77.2% (70.1-84.1) for those who had
downstaging. Five-year estimated cancer-specific survival
probability was 73.6% (61.8-87.7) for those who did not have
downstaging compared to 83.6% (77.8-89.7) for those who had
downstaging. Five-year estimated recurrence-free survival
probability was 68.1% (56.0-82.8) for those who did not have
downstaging compared to 72.1% (65.7-79.1) for those who
had downstaging.Frontiers in Oncology | www.frontiersin.org 7Univariate and Multivariate Analysis
At univariate analysis (Tables 1–7), the number of neoadjuvant
cycles was not associated with either pathologic complete
response, pathologic downstaging, time to recurrence, cancer
specific, and overall survival. Of note, patients in cohort B vs. A
showed a worse non-cancer specific overall survival at univariate
analysis (HR= 2.53; 95 CI= 1.05- 6.10; p=0.046), although this
finding was not confirmed at multivariate analysis.
At multivariate analysis (Tables 1–7), Erythrocyte
Sedimentation Rate was associated with complete pathologic
response (p=0.084; HR=0,98; 95% CI: 0,95 to 1,00), NLR was
associated with overall survival (p= 0,040; HR=1,16; 95% CI: 1,01
to 1,34), preoperative total cholesterol was associated with
cancer-specific survival (p= 0,001; HR=1,02; 95% CI: 1,01 to
1,02), preoperative fibrinogen was associated with non-cancer
specific survival (HR=0.50; 95% CI= 0.29 to 0.87; p=0.014),
platelet count was associated with time to recurrence (p=0,016;
HR=1,00; 95% CI: 1,00 to 1,00).DISCUSSION
Neo-adjuvant chemotherapy based on cisplatin has represented
the standard of care in patients with T2-T4 UBC for the past two
decades (14), although the optimal schedule and number ofTABLE 2 | Uni- and multi-variate analysis of the number of cycles and other baseline variables as potential predictors of downstaging.
Variable Downstaging
Univariate Multivariate
OR 95% CI p-value aOR 95% CI p-value
Number of neoadjuvant cisplatin-gemcitabine cycles 0.65 0.33, 1.32 0.224 – – –
Clinical T stage
<=2 Reference – Reference
>=3 0.86 0.45, 1.67 0.655 – – –
Sex
Male Reference – Reference
Female 1.56 0.65, 4.37 0.352 – – –
Age 0.96 0.93, 0.99 0.017 0.99 0.95, 1.03 0.662
Ecog 0.57 0.41, 0.78 <0.001 0.70 0.44, 1.09 0.120
Charlson index 1.00 0.86, 1.19 0.960 – – –
HB (g/dl) 0.99 0.97, 1.01 0.148 – – –
Creatinine (mg/dl) 1.47 0.81, 3.36 0.246 – – –
PCR (mg/L) 0.95 0.91, 0.98 0.004 0.95 0.89, 1.01 0.131
VES (mm/h) 0.98 0.96, 1.00 0.025 0.99 0.97, 1.02 0.549
NLR 0.87 0.72, 1.04 0.130 – – –
Neutrophils x10^3/µL 0.99 0.96, 1.03 0.487 – – –
Lymphocytes x10^3/µL 0.99 0.89, 1.15 0.881 – – –
Monocytes x10^3/µL 1.06 0.84, 1.40 0.634 – – –
Eosinophils x10^3/µL 1.09 0.59, 3.38 0.812 – – –
Basophils x10^3/µL 0.36 0.00, 176 0.731 – – –
Platelets x10^3/µL 1.00 1.00, 1.00 0.962 – – –
Albumin (g/dl) 1.44 0.78, 2.66 0.246 – – –
BMI 1.10 1.00, 1.21 0.048 1.05 0.95, 1.16 0.347
Total cholesterol level (mg/dl) 0.99 0.99, 1.00 0.134 – – –
HDL (mg/dl) 0.99 0.97, 1.01 0.449 – – –
Fibrinogen level (mg/dl) 0.92 0.71, 1.19 0.507 – – –
Preoperative PCR (mg/L) 0.95 0.91, 0.99 0.025 1.01 0.94, 1.08 0.847May 2021 | Volume 11 | ArticleP-values and OR are computed with single and multiple logistic regression. Significant values are highlighted in bold.651745
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meta-analysis (9) that analyzed data collected in 15 randomized
trials enrolling a total of 3,285 patients neoadjuvant regimens
based on cisplatin alone were not associated with any survival
benefit, which was only provided by cisplatin-containing
regimens including cisplatin-gemcitabine or MVAC ‐like
chemotherapy (HR, 0.82; 95% CI, 0.74–0.91; p <.001; p = .99
for heterogeneity, I2 = 0%). This meta-analysis did not identify
any differences in outcomes associated with GC vs. MVAC. Data
collected from 12 trials of 1,734 patients, including 1,067 patients
receiving gemcitabine-cisplatin and 667 patients receiving
MVAC, showed that pCR was 25.7% in patients treated with
CG and 24.3% in those receiving MVAC. Similarly, data
collected from 10 trials of 1,495 patients, including 898
patients receiving GC and 597 patients receiving MVAC,
showed no significant difference between GC and MVAC in
terms of pathologic downstaging rate (odds ratio, 1.07; 95% CI,
0.85–1.34). Finally, data collected from 7 trials studies, including
1,414 patients, showed that GC vs. MVAC was associated with
worse overall survival (HR, 1.26; 95% CI, 1.01–1.57; p = .94 for
heterogeneity, I2 = 0%), although this difference was not
statistically significant after excluding patients treated with
carboplatin (9).
In a phase II trial that randomized 237 bladder cancer
patients to dose dense MVAC, administered every 14 days forFrontiers in Oncology | www.frontiersin.org May 2021 | Volume 11 | Article 65174584 cycles, or gemcitabine-cisplatin, administered every 21 days for
4 cycles, the pT0 rates for ddMVAC and GC were 32% and 35%,
respectively (15). In a recently published randomized phase III
trial (12) designed to compare the efficacy of dose dense (dd)-
MVAC or GC in the neoadjuvant/adjuvant setting, 500 patients
were randomized to either either six cycles of dd-MVAC every 2
weeks or four cycles of GC every 3 weeks. Of note, in the
neoadjuvant group, 218 patients were treated with dd-MVAC
(60% received the planned six cycles) and 219 were treated with
GC (84% received the planned four cycles). A complete
pathological response rate of 42% and 36% was obtained in the
dd-MVAC vs. GC arms. In a retrospective observational study
that included data from 212 patients muscle-invasive UBC
treated with neoadjuvant chemotherapy (146 patients treated
with GC and 66 patients treated with MVAC, the pCR rate was
29% in the MVAC cohort and 31% in the GC cohort, with a
median of 3 cycles of chemotherapy administered and no
significant difference in the pathologic response rate among
the two regimens (16). In another retrospective study (13)
including 42 patients receiving 4 cycles of neoadjuvant GC, the
complete pathologic response rate was 26% (95% confidence
interval [CI], 14-42), and no residual muscle-invasive disease
proportion (<pT2) was 36% (95% CI, 21-52); pT0 was achieved
in 28% (95% CI, 16-42) and <pT2 in 35% (95% CI, 23-49) of
54 MVAC-treated patients. All 15 GC patients achieving <pT2TABLE 3 | Uni- and multi-variate analysis of the number of cycles and other baseline variables as potential predictors of complete response.
Variable Complete pathologic response
Univariate Multivariate
OR 95% CI p-value aOR 95% CI p-value
Number of cycles 0.97 0.46, 1.96 0.941 – – –
Clinical T stage
<=2 Reference – Reference
>=3 1.47 0.77, 2.78 0.243 – – –
Sex
Male Reference – Reference
Female 0.75 0.29, 1.73 0.512 – – –
Age 0.98 0.95, 1.01 0.158 – – –
Ecog 0.81 0.53, 1.16 0.254 – – –
Charlson index 0.96 0.81, 1.13 0.648 – – –
HB (g/dl) 1.00 0.98, 1.02 0.647 – – –
Creatinine (mg/dl) 0.80 0.39, 1.36 0.460 – – –
PCR (mg/L) 1.00 0.96, 1.03 0.931 – – –
VES (mm/h) 0.98 0.95, 1.00 0.043 0.98 0.95, 1.00 0.084
NLR 0.93 0.75, 1.12 0.450 – – –
Neutrophils x10^3/µL 1.01 0.97, 1.04 0.519 – – –
Lymphocytes x10^3/µL 1.05 0.94, 1.17 0.364 – – –
Monocytes x10^3/µL 1.30 1.06, 1.62 0.012 1.28 1.04, 1.58 0.019
Eosinophils x10^3/µL 1.03 0.42, 1.87 0.932 – – –
Basophils x10^3/µL 0.19 0.00, 64.7 0.599 – – –
Platelets x10^3/µL 1.00 1.00, 1.00 0.499 – – –
Albumin (g/dl) 1.13 0.61, 2.10 0.703 – – –
BMI 1.05 0.96, 1.15 0.269 – – –
Total cholesterol level (mg/dl) 1.00 1.00, 1.01 0.281 – – –
HDL (mg/dl) 1.00 0.97, 1.02 0.709 – – –
Fibrinogen level (mg/dl) 0.91 0.69, 1.18 0.491 – – –
Preoperative PCR (mg/L) 0.99 0.94, 1.04 0.719 – – –P-values and OR are computed with single and multiple logistic regression. Significant values are highlighted in bold.
Ferro et al. Neoadjuvant Chemotherapy for Bladder Cancerpathologic stage remained disease-free at a median follow-up of
30 months.
In another retrospective study, including 58 patients treated
with neoadjuvant GC therapy and 74 treated with neoadjuvant
MVAC, similar pathologic complete response rates were
obtained (20.7% vs. 18.9%, P = 0.83, respectively). Of note,
while neoadjuvant GC yielded improved 2-year OS rate than
neoadjuvant MVAC for clinical T2 disease (95.2% vs. 70.8%, P =
0.036), in patients with T3 or more advanced disease,
neoadjuvant MVAC provided more pT0 (20.0% vs. 5.6%, P =
0.07) and better 2-year OS than neoadjuvant GC (71.1% vs.
55.0%, P = 0.142), although the difference was not statistically
significant (17).
Of note, in our retrospective study, we obtained a complete
pathologic response rate of 22,5% in patients receiving 3 cycles of
neoadjuvant cisplatin-gemcitabine and of 22% in patients
receiving 4 cycles of cisplatin-gemcitabine. These results are
consistent with the published data reviewed. Pathologic
complete response rates obtained with immune checkpoint
inhibitors may be higher. While The PURE-01 trial reported
that pembrolizumab was associated with a 37% complete
response (pT0) after neoadjuvant therapy, the ABACUS trial
showed that atezolizumab yielded a complete response rate of
31%. Conversely, preoperative combination of ipilimumab +Frontiers in Oncology | www.frontiersin.org 9nivolumab (18), cisplatin plus gemcitabine plus pembrolizumab
(19), durvalumab + tremelimumab (20), was associated with a
complete pathologic response rate of 46%, 44, 34.8%, respectively.
Combination of 4 cycles of cisplatin-gemcitabine plus 4 cycles of
nivolumab in the BLASST-1 trial was able to yield a complete
pathologic response rate in 20 of 41 of patients or 49% of patients
(21). Of note, the results obtained in our retrospective study in
terms of pathologic complete response rate are lower than
expected in both cohorts, although we cannot provide an
explanation for this finding. Importantly, not only did we not
identify any differences in cancer-specific survival or time to
recurrence among patients treated with 3 vs. 4 cycles, but we
reported that non-cancer specific survival was worse in patients
receiving an additional cycle(HR= 2.53; 95 CI= 1.05- 6.10;
p=0.046). When we analyzed all available baseline variables
between the two cohorts, we did not identify any difference that
may explain this finding. Considering that long-term platinum-
induced cardiovascular toxicity has been shown in young patients
treated for germ-cell tumors (22), we speculate that an additional
cycle may increase mid- and long-term cardiovascular toxicity
with an increased risk of death in a population who is generally at
high or very cardiovascular high risk (males, elderly, heavy
smokers). As reported by others (13), we confirmed that
pathologic downstaging and complete response were associatedTABLE 4 | Uni- and multi-variate analysis of the number of cycles and other baseline variables as potential predictors of overall survival.
Variable Overall survival
Univariate Multivariate
HR 95% CI p-value aHR 95% CI p-value
Number of cycles
3 Reference – Reference Reference – Reference
4 1.63 0.99, 2.69 0.061 1.66 0.99, 2.80 0.056
Clinical T stage
<=2 Reference – Reference
>=3 0.85 0.52, 1.41 0.532 – – –
Sex
Male Reference – Reference – – –
Female 1.57 0.90, 2.76 0.129 – – –
Age 0.97 0.73, 1.28 0.811 – – –
Ecog 0.97 0.85, 1.11 0.644 – – –
Charlson index 1.00 0.98, 1.02 0.992 – – –
HB (g/dl) 0.65 0.37, 1.14 0.083 1.00 0.98, 1.02 0.968
Creatinine (mg/dl) 1.02 0.99, 1.04 0.250 – – –
PCR (mg/L) 1.02 1.00, 1.03 0.013 1.01 0.99, 1.03 0.374
VES (mm/h) 1.25 1.10, 1.42 0.001 1.01 1.00, 1.03 0.142
NLR 1.03 1.01, 1.05 0.011 1.16 1.01, 1.34 0.040
Neutrophils x10^3/µL 1.04 0.96, 1.12 0.397 – – –
Lymphocytes x10^3/µL 1.06 0.90, 1.25 0.514 – – –
Monocytes x10^3/µL 1.55 1.15, 2.07 0.030 1.12 0.96, 1.32 0.160
Eosinophils x10^3/µL 0.78 0.01, 70.9 0.915 – – –
Basophils x10^3/µL 1.00 1.00, 1.00 0.688 – – –
Platelets x10^3/µL 0.63 0.39, 1.00 0.050 1.00 1.00, 1.00 0.641
Albumin (g/dl) 0.91 0.85, 0.98 0.007 0.68 0.42, 1.12 0.131
BMI 1.01 1.01, 1.02 <0.001 0.95 0.88, 1.03 0.187
Total cholesterol level (mg/dl) 1.01 0.99, 1.02 0.401 – – –
HDL (mg/dl) 0.89 0.73, 1.10 0.276 – – –
Fibrinogen level (mg/dl) 1.00 0.97, 1.04 0.973 – – –
Preoperative PCR (mg/L) 1.00 0.97, 1.02 0.766 – – –May 2021 | Volume 11 | ArticP-values and HR are computed with single and multiple Cox regression. Significant values are highlighted in bold.le 651745
Ferro et al. Neoadjuvant Chemotherapy for Bladder CancerTABLE 5 | Uni- and multi-variate analysis of the number of cycles and other baseline variable as potential predictors of cancer-specific survival.
Variable Cancer specific survival
Univariate Multivariate
HR 95% CI p-value aHR 95% CI p-value
Number of cycles
3 Reference – Reference Reference – Reference
4 1.28 0.70, 2.36 0.428 1.14 0.59, 2.20 0.690
Clinical T stage
<=2 Reference – Reference
>=3 0.81 0.45, 1.46 0.485 – – –
Sex
Male Reference – Reference
Female 1.28 0.64, 2.56 0.499 – – –
Age 0.99 0.96, 1.02 0.628 – – –
Ecog 1.02 0.75, 1.40 0.888 – – –
Charlson index 1.05 0.92, 1.22 0.470 – – –
HB (g/dl) 1.00 0.98, 1.02 0.756 – – –
Creatinine (mg/dl) 0.44 0.20, 0.99 0.018 0.56 0.23, 1.34 0.194
PCR (mg/L) 1.02 0.99, 1.05 0.184 – – –
VES (mm/h) 1.03 1.01, 1.04 0.002 1.01 0.99, 1.03 0.339
NLR 1.34 1.17, 1.54 <0.001 1.07 0.89, 1.30 0.462
Neutrophils x10^3/µL 1.04 1.02, 1.05 0.002 1.02 0.99, 1.04 0209
Lymphocytes x10^3/µL 1.06 0.99, 1.13 0.179 – – –
Monocytes x10^3/µL 1.15 0.98, 1.35 0.129 – – –
Eosinophils x10^3/µL 1.66 1.24, 2.22 0.014 1.20 0.79, 1.84 0.397
Basophils x10^3/µL 1.23 0.01, 205 0.937 – – –
Platelets x10^3/µL 1.00 1.00, 1.00 0.181 – – –
Albumin (g/dl) 0.54 0.32, 0.94 0.030 0.64 0.34, 1.19 0.160
BMI 0.92 0.85, 1.00 0.045 0.94 0.85, 1.03 0.202
Total cholesterol level (mg/dl) 1.02 1.01, 1.03 <0.001 1.02 1.01, 1.02 <0.001
HDL (mg/dl) 1.00 0.98, 1.02 0.852 – – –
Fibrinogen level (mg/dl) 1.00 0.80, 1.26 0.972 – – –
Preoperative PCR (mg/L) 1.00 0.96, 1.04 0.993 – – –Frontiers in Oncology | www.frontiersin.org 10 May 2021 | Volume 11 | ArticP-values and HR are computed with single and multiple Cox regression. Significant values are highlighted in bold.TABLE 6 | Uni- and multi-variate analysis of the number of cycles and other baseline variable as potential predictors of non-cancer specific survival.
Variable Non-cancer survival, N = 170
Univariate Multivariate
HR 95% CI p-value aHR 95% CI p-value
Number of cycles
3 Reference – Reference Reference – Reference
4 2.53 1.05, 6.10 0.046 1.91 0.77, 4.74 0.160
Clinical T stage
<=2 Reference – Reference
>=3 0.97 0.40, 2.38 0.947 – – –
Sex
Male Reference – Reference – – –
Female 2.23 0.86, 5.79 0.123 – – –
Age at bc diagnosis 1.00 0.96, 1.05 0.933 – – –
Ecog 0.82 0.46, 1.47 0.484 – – –
Charlson index 0.76 0.57, 1.02 0.050 0.79 0.59, 1.07 0.127
HB (g/dl) 0.97 0.86, 1.10 0.481 – – –
Creatinine (mg/dl) 0.95 0.50, 1.80 0.877 – – –
PCR (mg/L) 1.00 0.95, 1.06 0.898 – – –
VES (mm/h) 1.00 0.97, 1.03 0.995 – – –
NLR 0.99 0.70, 1.41 0.974 – – –
Neutrophils x10^3/µL 0.85 0.66, 1.09 0.138 – – –
Lymphocytes x10^3/µL 0.60 0.32, 1.15 0.091 0.61 0.30, 1.22 0.163
(Continued)le 651745
Ferro et al. Neoadjuvant Chemotherapy for Bladder Cancerwith prognosis, with only 5 reported deaths among the 49 patients
with complete response vs. 62 reported deaths among the 170
patients without complete response.
In conclusion, although we are well aware of the limitations
of our retrospective study, which include the study design and
the limited sample size, this study represents the largest
specifically designed to capture potential differences inFrontiers in Oncology | www.frontiersin.org 11outcomes between 3 and 4 cycles of neo-adjuvant cisplatin-
gemcitabine. We found that 3 vs. 4 cycles may be equally
effective, with a signal of decreased overall mortality in
patients who received less cycles. Our finding may be
incorporated in novel combination prospective trials based on
cisplatin+gemcitabine +immune checkpoint inhibitors.
Prospective studies are warranted.TABLE 6 | Continued
Variable Non-cancer survival, N = 170
Univariate Multivariate
HR 95% CI p-value aHR 95% CI p-value
Monocytes x10^3/µL 0.64 0.35, 1.14 0.069 0.71 0.37, 1.36 0.299
Eosinophils x10^3/µL 0.32 0.01, 9.37 0.458 – – –
Basophils x10^3/µL 0.39 0.00, 1,67 0.821 – – –
Platelets x10^3/µL 1.00 0.99, 1.00 0.528 – – –
Albumin (g/dl) 0.99 0.41, 2.35 0.975 – – –
BMI 0.87 0.76, 0.99 0.035 0.88 0.77, 1.01 0.724
Total cholesterol level (mg/dl) 0.99 0.98, 1.01 0.350 – – –
HDL (mg/dl) 1.01 0.98, 1.04 0.470 – – –
Fibrinogen level (mg/dl) 0.56 0.34, 0.92 0.008 0.50 0.29, 0.87 0.014
Preoperative PCR (mg/L) 1.00 0.94, 1.06 0.958 – – –May 2021 | Volume 11 | ArticP-values and HR are computed with single and multiple Cox regression. Significant values are highlighted in bold.TABLE 7 | Uni- and multi-variate analysis of the number of cycles and other baseline variable as potential predictors of time to recurrence.
Variable Time to Recurrence
Univariate Multivariate
HR 95% CI p-value aHR 95% CI p-value
Number of cycles
3 Reference – Reference Reference – Reference
4 1.00 0.57, 1.74 0.996 1.13 0.63, 2.01 0.681
Clinical T stage
<=2 Reference – Reference
>=3 1.11 0.68, 1.83 0.676 – – –
Sex
Male Reference – Reference – – –
Female 1.12 0.60, 2.11 0.722 – – –
Age 1.01 0.98, 1.03 0.604 – – –
Ecog 1.26 0.99, 1.59 0.078 1.23 0.96, 1.57 0.095
Charlson index 1.01 0.89, 1.15 0.830 – – –
HB (g/dl) 0.97 0.91, 1.03 0.123 – – –
Creatinine (mg/dl) 0.89 0.57, 1.38 0.569 – – –
PCR (mg/L) 0.99 0.96, 1.02 0.506 – – –
VES (mm/h) 1.00 0.98, 1.02 0.924 – – –
NLR 1.04 0.90, 1.20 0.610 – – –
Neutrophils x10^3/µL 0.97 0.92, 1.03 0.184 – – –
Lymphocytes x10^3/µL 0.88 0.70, 1.11 0.131 – – –
Monocytes x10^3/µL 0.99 0.83, 1.18 0.909 – – –
Eosinophils x10^3/µL 0.66 0.24, 1.83 0.310 – – –
Basophils x10^3/µL 14.3 0.27, 761 0.215 – – –
Platelets 1.33 1.07, 1.66 0.015 1.31 1.05, 1.63 0.016
Albumin (g/dl) 1.00 0.63, 1.58 0.986 – – –
BMI 1.00 0.94, 1.07 0.982 – – –
Total cholesterol level (mg/dl) 1.00 1.00, 1.01 0.596 – – –
HDL (mg/dl) 0.99 0.97, 1.01 0.354 – – –
Fibrinogen level (mg/dl) 1.10 0.90, 1.33 0.353 – – –
Preoperative PCR (mg/L) 1.00 0.97, 1.04 0.933 – – –P-values and HR are computed with single and multiple Cox regression. Significant values are highlighted in bold.le 651745
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